Literature DB >> 20457818

Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART).

Daryl J Hoban1, Samuel K Bouchillon, Stephen P Hawser, Robert E Badal, Vincent J Labombardi, Joseph DiPersio.   

Abstract

During 2007-2008, 1,036 gram-negative bacilli were isolated from patients with complicated intra-abdominal infections in the United States. Against members of the family Enterobacteriaceae, the most active agents in vitro were ertapenem, imipenem, and amikacin, while the least active agent was ampicillin-sulbactam. Ertapenem and imipenem were active against all extended-spectrum-beta-lactamase (ESBL)-positive Escherichia coli. Antimicrobial resistance in gram-negative bacilli isolated from patients with complicated intra-abdominal infections in the United States continues to increase.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20457818      PMCID： PMC2897303          DOI： 10.1128/AAC.01808-09

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  11 in total

1.  Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections.

Authors:  Joseph S Solomkin; John E Mazuski; Ellen J Baron; Robert G Sawyer; Avery B Nathens; Joseph T DiPiro; Timothy Buchman; E Patchen Dellinger; John Jernigan; Sherwood Gorbach; Anthony W Chow; John Bartlett
Journal:  Clin Infect Dis       Date:  2003-09-25       Impact factor: 9.079

2.  In vitro susceptibilities of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: the 2003 Study for Monitoring Antimicrobial Resistance Trends (SMART).

Authors:  David L Paterson; Flávia Rossi; Fernando Baquero; Po-Ren Hsueh; Gail L Woods; Vilas Satishchandran; Theresa A Snyder; Charlotte M Harvey; Hedy Teppler; Mark J Dinubile; Joseph W Chow
Journal:  J Antimicrob Chemother       Date:  2005-04-22       Impact factor: 5.790

3.  Regional variation in the prevalence of extended-spectrum beta-lactamase-producing clinical isolates in the Asia-Pacific region (SENTRY 1998-2002).

Authors:  Yoichi Hirakata; Junichi Matsuda; Yoshitsugu Miyazaki; Shimeru Kamihira; Sayoko Kawakami; Yukihisa Miyazawa; Yasuo Ono; Nobuhiko Nakazaki; Yasuyoshi Hirata; Matsuhisa Inoue; John D Turnidge; Jan M Bell; Ronald N Jones; Shigeru Kohno
Journal:  Diagn Microbiol Infect Dis       Date:  2005-08       Impact factor: 2.803

4.  In vitro susceptibilities of aerobic and facultatively anaerobic Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: 2004 results from SMART (Study for Monitoring Antimicrobial Resistance Trends).

Authors:  Flávia Rossi; Fernando Baquero; Po-Ren Hsueh; David L Paterson; Grant V Bochicchio; Theresa A Snyder; Vilas Satishchandran; Kathleen McCarroll; Mark J DiNubile; Joseph W Chow
Journal:  J Antimicrob Chemother       Date:  2006-05-22       Impact factor: 5.790

5.  First report of the emergence of CTX-M-type extended-spectrum beta-lactamases (ESBLs) as the predominant ESBL isolated in a U.S. health care system.

Authors:  James S Lewis; Monica Herrera; Brian Wickes; Jan E Patterson; James H Jorgensen
Journal:  Antimicrob Agents Chemother       Date:  2007-08-27       Impact factor: 5.191

6.  Trends in the frequency of multiple drug-resistant Enterobacteriaceae and their susceptibility to ertapenem, imipenem, and other antimicrobial agents: data from the Study for Monitoring Antimicrobial Resistance Trends 2002 to 2007.

Authors:  Daryl J Hoban; Samuel K Bouchillon; Stephen P Hawser; Robert E Badal
Journal:  Diagn Microbiol Infect Dis       Date:  2009-09-05       Impact factor: 2.803

7.  In vitro susceptibilities of aerobic and facultatively anaerobic gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: 2005 results from Study for Monitoring Antimicrobial Resistance Trends (SMART).

Authors:  Fernando Baquero; Po-Ren Hsueh; David L Paterson; Flávia Rossi; Grant V Bochicchio; Gale Gallagher; Keith Lantz; Javier Baez Villasenor; Kathleen McCarroll; Murray A Abramson; Joseph W Chow
Journal:  Surg Infect (Larchmt)       Date:  2009-04       Impact factor: 2.150

8.  Emergence of high levels of extended-spectrum-beta-lactamase-producing gram-negative bacilli in the Asia-Pacific region: data from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program, 2007.

Authors:  Stephen P Hawser; Samuel K Bouchillon; Daryl J Hoban; Robert E Badal; Po-Ren Hsueh; David L Paterson
Journal:  Antimicrob Agents Chemother       Date:  2009-06-08       Impact factor: 5.191

9.  In vitro susceptibilities of aerobic and facultative anaerobic Gram-negative bacilli from patients with intra-abdominal infections worldwide from 2005-2007: results from the SMART study.

Authors:  Stephen P Hawser; Samuel K Bouchillon; Daryl J Hoban; Robert E Badal
Journal:  Int J Antimicrob Agents       Date:  2009-09-11       Impact factor: 5.283

10.  Clinical and microbiological profiles of community-acquired and nosocomial intra-abdominal infections: results of the French prospective, observational EBIIA study.

Authors:  Philippe Montravers; Alain Lepape; Luc Dubreuil; Rémy Gauzit; Yves Pean; Daniel Benchimol; Hervé Dupont
Journal:  J Antimicrob Chemother       Date:  2009-02-05       Impact factor: 5.790
View more
  14 in total

1.  Susceptibility of Klebsiella pneumoniae isolates from intra-abdominal infections and molecular characterization of ertapenem-resistant isolates.

Authors:  Stephen P Hawser; Samuel K Bouchillon; Christine Lascols; Meredith Hackel; Daryl J Hoban; Robert E Badal; Neil Woodford; David M Livermore
Journal:  Antimicrob Agents Chemother       Date:  2011-06-13       Impact factor: 5.191

2.  Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum β-lactamase bacteremia.

Authors:  Pranita D Tamma; Jennifer H Han; Clare Rock; Anthony D Harris; Ebbing Lautenbach; Alice J Hsu; Edina Avdic; Sara E Cosgrove
Journal:  Clin Infect Dis       Date:  2015-01-13       Impact factor: 9.079

3.  The times they are a-changin': carbapenems for extended-spectrum-β-lactamase-producing bacteria.

Authors:  Jesús Rodríguez-Baño
Journal:  Antimicrob Agents Chemother       Date:  2015-06-22       Impact factor: 5.191

4.  Impact of adopting minimum inhibitory concentration as the determinant of susceptibility to cephalosporins and carbapenems in multi-drug resistant Enterobacteriaceae.

Authors:  M Parta
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-09-13       Impact factor: 3.267

5.  Decreased susceptibility to noncarbapenem antimicrobials in extended-spectrum-β-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates in Toronto, Canada.

Authors:  Christopher F Lowe; Allison McGeer; Matthew P Muller; Kevin Katz
Journal:  Antimicrob Agents Chemother       Date:  2012-04-16       Impact factor: 5.191

Review 6.  Combination therapy for treatment of infections with gram-negative bacteria.

Authors:  Pranita D Tamma; Sara E Cosgrove; Lisa L Maragakis
Journal:  Clin Microbiol Rev       Date:  2012-07       Impact factor: 26.132

7.  Risk factors for hospital-acquired bloodstream infections caused by extended-spectrum β-lactamase Klebsiella pneumoniae among cancer patients.

Authors:  D Li; Y Chen; W Zhang; S Zheng; Q Zhang; C Bai; P Zhang
Journal:  Ir J Med Sci       Date:  2013-11-29       Impact factor: 1.568

8.  A Multinational, Preregistered Cohort Study of β-Lactam/β-Lactamase Inhibitor Combinations for Treatment of Bloodstream Infections Due to Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae.

Authors:  Belén Gutiérrez-Gutiérrez; Salvador Pérez-Galera; Elena Salamanca; Marina de Cueto; Esther Calbo; Benito Almirante; Pierluigi Viale; Antonio Oliver; Vicente Pintado; Oriol Gasch; Luis Martínez-Martínez; Johann Pitout; Murat Akova; Carmen Peña; José Molina; Alicia Hernández; Mario Venditti; Nuria Prim; Julia Origüen; German Bou; Evelina Tacconelli; Mario Tumbarello; Axel Hamprecht; Helen Giamarellou; Manel Almela; Federico Pérez; Mitchell J Schwaber; Joaquín Bermejo; Warren Lowman; Po-Ren Hsueh; Marta Mora-Rillo; Clara Natera; Maria Souli; Robert A Bonomo; Yehuda Carmeli; David L Paterson; Alvaro Pascual; Jesús Rodríguez-Baño
Journal:  Antimicrob Agents Chemother       Date:  2016-06-20       Impact factor: 5.191

9.  Phase 2, randomized, double-blind study of the efficacy and safety of two dose regimens of eravacycline versus ertapenem for adult community-acquired complicated intra-abdominal infections.

Authors:  Joseph S Solomkin; Mayakonda Krishnamurthy Ramesh; Gintaras Cesnauskas; Nikolajs Novikovs; Penka Stefanova; Joyce A Sutcliffe; Susannah M Walpole; Patrick T Horn
Journal:  Antimicrob Agents Chemother       Date:  2013-12-16       Impact factor: 5.191

10.  Global fluoroquinolone resistance epidemiology and implictions for clinical use.

Authors:  Axel Dalhoff
Journal:  Interdiscip Perspect Infect Dis       Date:  2012-10-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.